421 Initial results of a phase 1 trial of RP2, a first in class, enhanced potency, anti-CTLA-4 antibody expressing, oncolytic HSV as single agent and combined with nivolumab in patients with solid tumors
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| _version_ | 1818927554337177600 |
|---|---|
| author | Anna Olsson-Brown Joseph Sacco Mark Middleton Kevin Harrington Robert Coffin Howard Kaufman Suzanne Thomas Praveen Bommareddy Francesca Aroldi Pablo Nanclares Lavita Menezes Selda Samakoglu |
| author_facet | Anna Olsson-Brown Joseph Sacco Mark Middleton Kevin Harrington Robert Coffin Howard Kaufman Suzanne Thomas Praveen Bommareddy Francesca Aroldi Pablo Nanclares Lavita Menezes Selda Samakoglu |
| author_sort | Anna Olsson-Brown |
| collection | DOAJ |
| first_indexed | 2024-12-20T03:14:51Z |
| format | Article |
| id | doaj.art-ded3a2e10fe643758a8db510b6c2d64c |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-12-20T03:14:51Z |
| publishDate | 2020-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-ded3a2e10fe643758a8db510b6c2d64c2022-12-21T19:55:22ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262020-11-018Suppl 310.1136/jitc-2020-SITC2020.0421421 Initial results of a phase 1 trial of RP2, a first in class, enhanced potency, anti-CTLA-4 antibody expressing, oncolytic HSV as single agent and combined with nivolumab in patients with solid tumorsAnna Olsson-Brown0Joseph Sacco1Mark Middleton2Kevin Harrington3Robert Coffin4Howard Kaufman5Suzanne Thomas6Praveen Bommareddy7Francesca Aroldi8Pablo Nanclares9Lavita Menezes10Selda Samakoglu112University of Liverpool, Wirral, UK2University of Liverpool, Wirral, UK2Churchill Hospital, Oxford, UKAff11 grid.18886.3f0000000112714623The Institute of Cancer Research/The Royal Marsden Hospital London UK Aff14 grid.417886.40000 0001 0657 5612Amgen Woburn MA USA Aff15 grid.430387.b0000000419368796Rutgers Cancer Institute of New Jersey New Brunswick NJ USA Aff1 Replimune Inc 18 Commerce Way 01801 Woburn MA USA 10Replimune, Woburn, MA, USA1University of Oxford, Oxford, UK3The Institute of Cancer Research, London, UK4Replimune Inc., Woburn, MA, USA4Replimune Inc., Woburn, MA, USA |
| spellingShingle | Anna Olsson-Brown Joseph Sacco Mark Middleton Kevin Harrington Robert Coffin Howard Kaufman Suzanne Thomas Praveen Bommareddy Francesca Aroldi Pablo Nanclares Lavita Menezes Selda Samakoglu 421 Initial results of a phase 1 trial of RP2, a first in class, enhanced potency, anti-CTLA-4 antibody expressing, oncolytic HSV as single agent and combined with nivolumab in patients with solid tumors Journal for ImmunoTherapy of Cancer |
| title | 421 Initial results of a phase 1 trial of RP2, a first in class, enhanced potency, anti-CTLA-4 antibody expressing, oncolytic HSV as single agent and combined with nivolumab in patients with solid tumors |
| title_full | 421 Initial results of a phase 1 trial of RP2, a first in class, enhanced potency, anti-CTLA-4 antibody expressing, oncolytic HSV as single agent and combined with nivolumab in patients with solid tumors |
| title_fullStr | 421 Initial results of a phase 1 trial of RP2, a first in class, enhanced potency, anti-CTLA-4 antibody expressing, oncolytic HSV as single agent and combined with nivolumab in patients with solid tumors |
| title_full_unstemmed | 421 Initial results of a phase 1 trial of RP2, a first in class, enhanced potency, anti-CTLA-4 antibody expressing, oncolytic HSV as single agent and combined with nivolumab in patients with solid tumors |
| title_short | 421 Initial results of a phase 1 trial of RP2, a first in class, enhanced potency, anti-CTLA-4 antibody expressing, oncolytic HSV as single agent and combined with nivolumab in patients with solid tumors |
| title_sort | 421 initial results of a phase 1 trial of rp2 a first in class enhanced potency anti ctla 4 antibody expressing oncolytic hsv as single agent and combined with nivolumab in patients with solid tumors |
| work_keys_str_mv | AT annaolssonbrown 421initialresultsofaphase1trialofrp2afirstinclassenhancedpotencyantictla4antibodyexpressingoncolytichsvassingleagentandcombinedwithnivolumabinpatientswithsolidtumors AT josephsacco 421initialresultsofaphase1trialofrp2afirstinclassenhancedpotencyantictla4antibodyexpressingoncolytichsvassingleagentandcombinedwithnivolumabinpatientswithsolidtumors AT markmiddleton 421initialresultsofaphase1trialofrp2afirstinclassenhancedpotencyantictla4antibodyexpressingoncolytichsvassingleagentandcombinedwithnivolumabinpatientswithsolidtumors AT kevinharrington 421initialresultsofaphase1trialofrp2afirstinclassenhancedpotencyantictla4antibodyexpressingoncolytichsvassingleagentandcombinedwithnivolumabinpatientswithsolidtumors AT robertcoffin 421initialresultsofaphase1trialofrp2afirstinclassenhancedpotencyantictla4antibodyexpressingoncolytichsvassingleagentandcombinedwithnivolumabinpatientswithsolidtumors AT howardkaufman 421initialresultsofaphase1trialofrp2afirstinclassenhancedpotencyantictla4antibodyexpressingoncolytichsvassingleagentandcombinedwithnivolumabinpatientswithsolidtumors AT suzannethomas 421initialresultsofaphase1trialofrp2afirstinclassenhancedpotencyantictla4antibodyexpressingoncolytichsvassingleagentandcombinedwithnivolumabinpatientswithsolidtumors AT praveenbommareddy 421initialresultsofaphase1trialofrp2afirstinclassenhancedpotencyantictla4antibodyexpressingoncolytichsvassingleagentandcombinedwithnivolumabinpatientswithsolidtumors AT francescaaroldi 421initialresultsofaphase1trialofrp2afirstinclassenhancedpotencyantictla4antibodyexpressingoncolytichsvassingleagentandcombinedwithnivolumabinpatientswithsolidtumors AT pablonanclares 421initialresultsofaphase1trialofrp2afirstinclassenhancedpotencyantictla4antibodyexpressingoncolytichsvassingleagentandcombinedwithnivolumabinpatientswithsolidtumors AT lavitamenezes 421initialresultsofaphase1trialofrp2afirstinclassenhancedpotencyantictla4antibodyexpressingoncolytichsvassingleagentandcombinedwithnivolumabinpatientswithsolidtumors AT seldasamakoglu 421initialresultsofaphase1trialofrp2afirstinclassenhancedpotencyantictla4antibodyexpressingoncolytichsvassingleagentandcombinedwithnivolumabinpatientswithsolidtumors |